Upstream Bio, Inc. (UPB NASDAQ) stock market data APIs
$7.8147
-0.42(-5.4%)
as of March 4, 2026
Try our APIs with
free plan!
Upstream Bio, Inc. Financial Data Overview
Price chart is built with
Anychart
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Prev. Close
7.8147
Open
7.3926
High
8.0783
Low
7.3168
52 wk Range
5.14-33.68
Market Cap
1 261 M
Shares Outstanding
54 039 K
Revenue
2 799 K
EPS
-0.63
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Upstream Bio, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Upstream Bio, Inc. data using free add-ons & libraries
Get Upstream Bio, Inc. Fundamental Data
Upstream Bio, Inc. Fundamental data includes:
- Net Revenue: 2 799 K
- EBITDA: -140 332 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.78
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Upstream Bio, Inc. News
New
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also ...
Lowest Quant ranked small-cap stocks with positive EPS surprises
[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises r...
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose
Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen. Continue Reading
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat...
Get Upstream Bio, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
